Laura Naranjo

Barcelona, CT 08036, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 48 publications

IgA anti-β2-glycoprotein I as an independent risk factor in acute venous thromboembolism.

IgA anti-β2-glycoprotein I as an independent risk factor in acute venous thromboembolism.

Journal: Frontiers in immunology

Published: February 26, 2026

Atrophy signature for alpha-synuclein copathology in Alzheimer's disease.

Atrophy signature for alpha-synuclein copathology in Alzheimer's disease.

Journal: Alzheimer's & dementia (Amsterdam, Netherlands)

Published: January 26, 2026

Proteomic analysis in Alzheimer's disease and other dementias: a focus on sex-specific differences.

Proteomic analysis in Alzheimer's disease and other dementias: a focus on sex-specific differences.

Journal: Alzheimer's research & therapy

Published: January 20, 2026

Synucleinopathy-like clinical features and biologically defined synuclein seeding in PSP-Parkinsonism: an imperfect match.

Synucleinopathy-like clinical features and biologically defined synuclein seeding in PSP-Parkinsonism: an imperfect match.

Journal: NPJ Parkinson's disease

Published: December 29, 2025

Cytokine and Chemokine Profiles in Anti-LGI1 Encephalitis: Markers of Severity and Outcome.

Cytokine and Chemokine Profiles in Anti-LGI1 Encephalitis: Markers of Severity and Outcome.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: October 20, 2025

Plasma p-Tau217 and GFAP predict widespread cognitive decline in Alzheimer's disease.

Plasma p-Tau217 and GFAP predict widespread cognitive decline in Alzheimer's disease.

Journal: Journal of neurology

Published: October 09, 2025

α-Synuclein Seed Amplifications Assay in a Cohort With Cognitive Impairment: Performance and Interactions With CSF and Plasma Biomarkers.

α-Synuclein Seed Amplifications Assay in a Cohort With Cognitive Impairment: Performance and Interactions With CSF and Plasma Biomarkers.

Journal: Neurology

Published: September 08, 2025

An eight-year follow-up of the CMSAR: assessing how the new MDS criteria and biomarkers impact diagnostic accuracy.

An eight-year follow-up of the CMSAR: assessing how the new MDS criteria and biomarkers impact diagnostic accuracy.

Journal: NPJ Parkinson's disease

Published: June 16, 2025

Tremor and Ataxia in Paraneoplastic Anti-Diacylglycerol Lipase Alpha (DAGLA) Cerebellitis.

Tremor and Ataxia in Paraneoplastic Anti-Diacylglycerol Lipase Alpha (DAGLA) Cerebellitis.

Journal: Cerebellum (London, England)

Published: June 11, 2025

Criteria and non-criteria anti-phospholipid antibodies in the different clinical forms of antiphospholipid syndrome.

Criteria and non-criteria anti-phospholipid antibodies in the different clinical forms of antiphospholipid syndrome.

Journal: Frontiers in immunology

Published: May 27, 2025

Assessing Commercial Tissue-Based Assays for Autoimmune Neurologic Disorders (I): Antibodies to Intracellular Antigens.

Assessing Commercial Tissue-Based Assays for Autoimmune Neurologic Disorders (I): Antibodies to Intracellular Antigens.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: May 20, 2025

Assessing Commercial Tissue-Based Assays for Autoimmune Neurologic Disorders (II): Antibodies to Surface Antigens.

Assessing Commercial Tissue-Based Assays for Autoimmune Neurologic Disorders (II): Antibodies to Surface Antigens.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: May 20, 2025

Showing 1-12 of 48

Last Updated: 09/26/2026